Skip to content

Gene Biotherapeutics, Inc.: 10-Q filed 2013-08-14

What Gene Biotherapeutics, Inc. reported in its quarterly report filed 2013-08-14 (fiscal Q2 2013): 39 published measures, 101 facts as tagged in accession 0001193125-13-334329.

This filing

Form
10-Q (quarterly report)
Filed
2013-08-14
Fiscal period
fiscal Q2 2013
Accession
0001193125-13-334329 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Gene Biotherapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-06-305,481,002USD
At 2012-12-317,808,878USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-06-301,228,322USD
At 2012-12-311,443,088USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-06-304,252,680USD
At 2012-12-316,365,790USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-06-30658,559USD
At 2012-12-312,328,074USD
At 2012-06-306,271,500USD
At 2011-12-314,721,279USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-04-01 to 2013-06-30-2,117,548USD91
2013-01-01 to 2013-06-30-4,379,903USD181
2012-04-01 to 2012-06-30-1,875,447USD91
2012-01-01 to 2012-06-30-4,469,483USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-3,940,959USD181
2012-01-01 to 2012-06-30-4,980,804USD182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-01-01 to 2013-06-304,599USD181
2012-01-01 to 2012-06-3015,866USD182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2013-04-01 to 2013-06-30584,571USD91
2013-01-01 to 2013-06-301,183,776USD181
2012-04-01 to 2012-06-3013,174USD91
2012-01-01 to 2012-06-3033,652USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-06-302,276,043USD181
2012-01-01 to 2012-06-306,546,891USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-4,599USD181
2012-01-01 to 2012-06-30-15,866USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2013-06-30-100,794,228USD
At 2012-12-31-96,414,325USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-06-3061,694USD
At 2012-12-3197,582USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-06-3040,750USD181
2012-01-01 to 2012-06-3086,845USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-04-01 to 2013-06-30-2,117,020USD91
2013-01-01 to 2013-06-30-4,378,682USD181
2012-04-01 to 2012-06-30-1,876,870USD91
2012-01-01 to 2012-06-30-4,536,207USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-06-302,138,718USD
At 2012-12-314,288,739USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-04-01 to 2013-06-30528USD91
2013-01-01 to 2013-06-301,438USD181
2012-04-01 to 2012-06-30719USD91
2012-01-01 to 2012-06-302,114USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-06-301,216,622USD
At 2012-12-311,392,718USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-06-30723,746USD
At 2012-12-31777,861USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2013-06-30584,711USD
At 2012-12-31584,711USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2013-06-302,074,188USD
At 2012-12-312,218,010USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2013-06-30133,905USD
At 2012-12-31328,953USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-04-01 to 2013-06-302,362,441USD91
2013-01-01 to 2013-06-304,873,067USD181
2012-04-01 to 2012-06-301,883,948USD91
2012-01-01 to 2012-06-304,558,308USD182

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2013-06-30922,628USD
At 2012-12-311,174,323USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2013-04-01 to 2013-06-30245,421USD91
2013-01-01 to 2013-06-30494,385USD181
2012-04-01 to 2012-06-307,078USD91
2012-01-01 to 2012-06-3022,101USD182

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2013-04-01 to 2013-06-30339,150USD91
2013-01-01 to 2013-06-30689,391USD181
2012-04-01 to 2012-06-306,096USD91
2012-01-01 to 2012-06-3011,551USD182

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2013-04-01 to 2013-06-301,873,074USD91
2013-01-01 to 2013-06-303,621,258USD181
2012-04-01 to 2012-06-301,459,214USD91
2012-01-01 to 2012-06-302,968,975USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-04-01 to 2013-06-30489,367USD91
2013-01-01 to 2013-06-301,251,809USD181
2012-04-01 to 2012-06-30424,734USD91
2012-01-01 to 2012-06-301,589,333USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-06-306,614,149shares
At 2012-12-316,460,915shares

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2013-06-30943,076USD
At 2012-12-311,019,692USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2013-06-30186,689USD
At 2012-12-31184,836USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2013-06-30492,876USD
At 2012-12-31614,857USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2013-06-30423,626USD
At 2012-12-31407,389USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2013-04-01 to 2013-06-30-2,350,559USD91
2013-01-01 to 2013-06-30-4,612,914USD181
2012-04-01 to 2012-06-30-1,875,447USD91
2012-01-01 to 2012-06-30-4,469,483USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2013-01-01 to 2013-06-3040,487USD181
2012-01-01 to 2012-06-3048,575USD182

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2013-01-01 to 2013-06-3076,616USD181
2012-01-01 to 2012-06-300USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-01-01 to 2013-06-302,226,043USD181
2013-01-01 to 2013-03-3165,743USD90
2012-01-01 to 2012-06-306,396,891USD182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-195,048USD181
2012-01-01 to 2012-06-309,757USD182

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-314,126USD181
2012-01-01 to 2012-06-30337,737USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-54,115USD181
2012-01-01 to 2012-06-30-110,603USD182

Inspect the source

Entity
Gene Biotherapeutics, Inc. / CIK 0000772320
Captured
SEC response SHA-256
e91552cfabee8416dbcf0b8fa878884f925550f547c9b83f09dd1693554ad83d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000772320.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))